Imunon, Inc.
IMNNDrugs in Pipeline
7
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
ThermoDox
Hepatocellular Carcinoma
5% Dextrose Solution
Hepatocellular Carcinoma
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
Epithelial Ovarian Cancer
IMNN-001
Epithelial Ovarian Cancer
Paclitaxel
Ovarian Cancer
IMNN-101
SARS CoV 2 Infection
ThermoDox in combination with Microwave Hyperthermia (heat)
Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ThermoDox | Phase 3 | Hepatocellular Carcinoma | - | - |
5% Dextrose Solution | Phase 3 | Hepatocellular Carcinoma | - | - |
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) | Phase 3 | Epithelial Ovarian Cancer | - | - |
IMNN-001 | Phase 2 | Epithelial Ovarian Cancer | - | - |
Paclitaxel | Phase 2 | Ovarian Cancer | - | - |
IMNN-101 | Phase 2 | SARS CoV 2 Infection | - | - |
ThermoDox in combination with Microwave Hyperthermia (heat) | Phase 2 | Breast Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Imunon, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Imunon, Inc.'s (IMNN) pipeline across Phase 3, Phase 2. Its lead program is ThermoDox (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Imunon, Inc.'s next FDA catalyst?→
Imunon, Inc.'s (IMNN) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMNN biotech catalysts?→
Add IMNN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Imunon, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.